Asset
AXATILIMAB
Syndax Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04415073 | phase2 | terminated | 2020-05-30 | 2020-07-13 | Syndax Pharmaceuticals | A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19 |
FDA applications (0)
This company has no applications containing this asset.